Literature DB >> 8122731

Cytokines in plasma and ultrafiltrate during continuous arteriovenous haemofiltration.

E Tønnesen1, M B Hansen, K Höhndorf, M Diamant, K Bendtzen, M Wanscher, P Toft.   

Abstract

Cytokines are considered to be important mediators in the pathophysiology of sepsis and septic shock. We investigated if continuous arteriovenous haemofiltration (CAVH) could be used to remove excessive amounts of the cytokines tumour necrosis factor-alpha (TNF alpha), interleukin (IL)-1 alpha and IL-6 from peripheral blood in critically ill patients. Nine septic patients with renal failure were treated with CAVH. Ultrafiltrate and plasma were tested for cytokines by ELISA. All patients had detectable TNF alpha and IL-6 plasma levels, ranging from 10-750 pg/ml and 50-4,575 pg/ml, respectively. TNF alpha was removed by the ultrafiltrate with concentrations ranging from 10-1,000 pg/ml. The TNF alpha levels were significantly higher in the ultrafiltrate samples than in the corresponding plasma samples (P < 0.003). IL-6 was undetectable in the ultrafiltrate from five of the patients despite concomitant high plasma levels. IL-1 alpha was detectable in both plasma and ultrafiltrate in four patients. All patients developed multi-organ failure and septic shock and seven died. It is concluded that TNF alpha and IL-1 alpha but not IL-6 can be removed by CAVH in patients with sepsis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8122731     DOI: 10.1177/0310057X9302100603

Source DB:  PubMed          Journal:  Anaesth Intensive Care        ISSN: 0310-057X            Impact factor:   1.669


  2 in total

1.  Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis.

Authors:  J N Hoffmann; W H Hartl; R Deppisch; E Faist; M Jochum; D Inthorn
Journal:  Intensive Care Med       Date:  1996-12       Impact factor: 17.440

2.  The immunological effects of continuous veno-venous haemodiafiltration in critically ill patients.

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.